Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-group study of Jivi in previously treated children aged 7 to under 12 years with severe hemophilia A
2021-004858-30Phase 3Active
- Sponsor
- Bayer Consumer Health
- Start
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of damoctocog alfa pegol in hemophilia A, sponsored by Bayer Consumer Health. Primary endpoint: Adverse events of special interest associated with the first 4 exposure days leading to discontinuation. Started Jun 2022; status: active.
02
Drugs
damoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2021-004858-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004858-30.